PubMed:7843230 JSONTXT

{"project":"MyTest","denotations":[{"id":"T10","span":{"begin":524,"end":527},"obj":"Protein"},{"id":"T12","span":{"begin":528,"end":531},"obj":"Protein"},{"id":"T14","span":{"begin":559,"end":562},"obj":"Protein"},{"id":"T16","span":{"begin":563,"end":568},"obj":"Protein"},{"id":"T17","span":{"begin":1091,"end":1118},"obj":"Protein"},{"id":"T18","span":{"begin":1163,"end":1176},"obj":"Chemical"},{"id":"T19","span":{"begin":815,"end":818},"obj":"Protein"},{"id":"T20","span":{"begin":933,"end":936},"obj":"Protein"},{"id":"T21","span":{"begin":1191,"end":1194},"obj":"Protein"},{"id":"T22","span":{"begin":905,"end":908},"obj":"Protein"},{"id":"T23","span":{"begin":1848,"end":1851},"obj":"Protein"},{"id":"T25","span":{"begin":823,"end":828},"obj":"Protein"},{"id":"T26","span":{"begin":890,"end":895},"obj":"Protein"},{"id":"T27","span":{"begin":1199,"end":1204},"obj":"Protein"},{"id":"T28","span":{"begin":1833,"end":1838},"obj":"Protein"},{"id":"T3","span":{"begin":1791,"end":1794},"obj":"Protein"},{"id":"T30","span":{"begin":1397,"end":1406},"obj":"Protein"},{"id":"T31","span":{"begin":1120,"end":1129},"obj":"Protein"},{"id":"T32","span":{"begin":1629,"end":1638},"obj":"Protein"},{"id":"T33","span":{"begin":238,"end":245},"obj":"Cell"},{"id":"T4","span":{"begin":1799,"end":1804},"obj":"Protein"},{"id":"T5","span":{"begin":1651,"end":1660},"obj":"Protein"},{"id":"T7","span":{"begin":303,"end":306},"obj":"Protein"},{"id":"T8","span":{"begin":355,"end":391},"obj":"Protein"},{"id":"T35","span":{"begin":1479,"end":1489},"obj":"Protein_complex"},{"id":"T36","span":{"begin":307,"end":317},"obj":"Protein_complex"},{"id":"T37","span":{"begin":1734,"end":1744},"obj":"Protein_complex"},{"id":"T39","span":{"begin":20,"end":42},"obj":"Protein_complex"},{"id":"T41","span":{"begin":141,"end":168},"obj":"Protein_complex"}],"attributes":[{"id":"A6","pred":"db_id","subj":"T14","obj":"uniprot:P19838"},{"id":"A20","pred":"db_id","subj":"T31","obj":"uniprot:P01375"},{"id":"A19","pred":"db_id","subj":"T30","obj":"uniprot:P01375"},{"id":"A13","pred":"db_id","subj":"T22","obj":"uniprot:P19838"},{"id":"A9","pred":"db_id","subj":"T18","obj":"mesh:D003513"},{"id":"A5","pred":"db_id","subj":"T12","obj":"uniprot:Q04206"},{"id":"A25","pred":"db_id","subj":"T39","obj":"wikipedia:NF-κB"},{"id":"A1","pred":"db_id","subj":"T5","obj":"uniprot:P01375"},{"id":"A12","pred":"db_id","subj":"T21","obj":"uniprot:Q04206"},{"id":"A14","pred":"db_id","subj":"T23","obj":"uniprot:P19838"},{"id":"A4","pred":"db_id","subj":"T10","obj":"uniprot:P19838"},{"id":"A22","pred":"db_id","subj":"T35","obj":"wikipedia:NF-κB"},{"id":"A17","pred":"db_id","subj":"T27","obj":"uniprot:Q04864"},{"id":"A3","pred":"db_id","subj":"T8","obj":"uniprot:P01589"},{"id":"A10","pred":"db_id","subj":"T19","obj":"uniprot:Q04206"},{"id":"A2","pred":"db_id","subj":"T7","obj":"uniprot:P19838"},{"id":"A18","pred":"db_id","subj":"T28","obj":"uniprot:Q04864"},{"id":"A23","pred":"db_id","subj":"T36","obj":"wikipedia:NF-κB"},{"id":"A16","pred":"db_id","subj":"T26","obj":"uniprot:Q04864"},{"id":"A15","pred":"db_id","subj":"T25","obj":"uniprot:Q04864"},{"id":"A21","pred":"db_id","subj":"T32","obj":"uniprot:P01375"},{"id":"A8","pred":"db_id","subj":"T17","obj":"P01375"},{"id":"A11","pred":"db_id","subj":"T20","obj":"uniprot:Q04206"},{"id":"A7","pred":"db_id","subj":"T16","obj":"uniprot:Q04864"},{"id":"A24","pred":"db_id","subj":"T37","obj":"wikipedia:NF-κB"},{"id":"A26","pred":"db_id","subj":"T41","obj":"wikipedia:NF-κB"}],"namespaces":[{"prefix":"_base","uri":"https://www.uniprot.org/uniprot/testbase"},{"prefix":"UniProtKB","uri":"https://www.uniprot.org/uniprot/"},{"prefix":"uniprot","uri":"https://www.uniprot.org/uniprotkb/"}],"text":"Biphasic control of nuclear factor-kappa B activation by the T cell receptor complex: role of tumor necrosis factor alpha.\nThe regulation of nuclear factor (NF)-kappa B activation by the T cell receptor (TcR)/CD3 complex in primary human T cells has been studied at various times after activation. Only p50 NF-kappa B protein bound the kappa B element of interleukin-2 receptor (IL-2R) alpha chain promoter on resting T cells. However, immediately after TcR/CD3 cross-linking (after approximately 1 h; immediate) binding of p50.p65 heterodimers was observed. p50.c-rel heterodimers were also detected bound to this sequence at early time points (7-16 h; early), and both remained active at later time points (40 h; late) after activation. This regulation takes place mainly at the level of nuclear translocation of p65 and c-rel, at immediate and early time points. Activation also induced c-rel and p105/p50 mRNA synthesis, but not p65 mRNA whose expression was constitutive. Interestingly, all those early and late events, but not the immediate ones, were inhibited by a neutralizing anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody. Similarly, cycloheximide prevented the p65 and c-rel translocation and consequent formation of active binding heterodimers, at early and late times. Cyclosporin A impaired not only early and late, but also immediate events; however, addition of TNF-alpha prevented all inhibition. These results indicate that the regulation of NF-kappa B activation during T cell activation by TcR/CD3 signals is biphasic: TcR/CD3 triggers its immediate translocation, which is transient if no TNF-alpha is present. TNF-alpha, therefore, emerges as the main factor responsible for a second phase of NF-kappa B regulation, controlling both translocation of p65 and c-rel, and new mRNA synthesis for c-rel and p105/p50."}

{"project":"jnlpba-st-training","denotations":[{"id":"T1","span":{"begin":20,"end":42},"obj":"protein"},{"id":"T2","span":{"begin":61,"end":84},"obj":"protein"},{"id":"T3","span":{"begin":94,"end":121},"obj":"protein"},{"id":"T4","span":{"begin":141,"end":168},"obj":"protein"},{"id":"T5","span":{"begin":187,"end":220},"obj":"protein"},{"id":"T6","span":{"begin":238,"end":245},"obj":"cell_type"},{"id":"T7","span":{"begin":303,"end":325},"obj":"protein"},{"id":"T8","span":{"begin":336,"end":351},"obj":"DNA"},{"id":"T9","span":{"begin":355,"end":406},"obj":"DNA"},{"id":"T10","span":{"begin":418,"end":425},"obj":"cell_type"},{"id":"T11","span":{"begin":454,"end":461},"obj":"protein"},{"id":"T12","span":{"begin":524,"end":544},"obj":"protein"},{"id":"T13","span":{"begin":559,"end":581},"obj":"protein"},{"id":"T14","span":{"begin":815,"end":818},"obj":"protein"},{"id":"T15","span":{"begin":823,"end":828},"obj":"protein"},{"id":"T16","span":{"begin":933,"end":941},"obj":"RNA"},{"id":"T17","span":{"begin":1086,"end":1150},"obj":"protein"},{"id":"T18","span":{"begin":1191,"end":1194},"obj":"protein"},{"id":"T19","span":{"begin":1199,"end":1204},"obj":"protein"},{"id":"T20","span":{"begin":1397,"end":1406},"obj":"protein"},{"id":"T21","span":{"begin":1479,"end":1489},"obj":"protein"},{"id":"T22","span":{"begin":1529,"end":1536},"obj":"protein"},{"id":"T23","span":{"begin":1558,"end":1565},"obj":"protein"},{"id":"T24","span":{"begin":1629,"end":1638},"obj":"protein"},{"id":"T25","span":{"begin":1651,"end":1660},"obj":"protein"},{"id":"T26","span":{"begin":1734,"end":1744},"obj":"protein"},{"id":"T27","span":{"begin":1791,"end":1794},"obj":"protein"},{"id":"T28","span":{"begin":1799,"end":1804},"obj":"protein"},{"id":"T29","span":{"begin":1814,"end":1818},"obj":"RNA"},{"id":"T30","span":{"begin":1833,"end":1838},"obj":"protein"},{"id":"T31","span":{"begin":1843,"end":1851},"obj":"protein"}],"text":"Biphasic control of nuclear factor-kappa B activation by the T cell receptor complex: role of tumor necrosis factor alpha.\nThe regulation of nuclear factor (NF)-kappa B activation by the T cell receptor (TcR)/CD3 complex in primary human T cells has been studied at various times after activation. Only p50 NF-kappa B protein bound the kappa B element of interleukin-2 receptor (IL-2R) alpha chain promoter on resting T cells. However, immediately after TcR/CD3 cross-linking (after approximately 1 h; immediate) binding of p50.p65 heterodimers was observed. p50.c-rel heterodimers were also detected bound to this sequence at early time points (7-16 h; early), and both remained active at later time points (40 h; late) after activation. This regulation takes place mainly at the level of nuclear translocation of p65 and c-rel, at immediate and early time points. Activation also induced c-rel and p105/p50 mRNA synthesis, but not p65 mRNA whose expression was constitutive. Interestingly, all those early and late events, but not the immediate ones, were inhibited by a neutralizing anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody. Similarly, cycloheximide prevented the p65 and c-rel translocation and consequent formation of active binding heterodimers, at early and late times. Cyclosporin A impaired not only early and late, but also immediate events; however, addition of TNF-alpha prevented all inhibition. These results indicate that the regulation of NF-kappa B activation during T cell activation by TcR/CD3 signals is biphasic: TcR/CD3 triggers its immediate translocation, which is transient if no TNF-alpha is present. TNF-alpha, therefore, emerges as the main factor responsible for a second phase of NF-kappa B regulation, controlling both translocation of p65 and c-rel, and new mRNA synthesis for c-rel and p105/p50."}

{"project":"genia-medco-coref","denotations":[{"id":"C2","span":{"begin":57,"end":84},"obj":"NP"},{"id":"C1","span":{"begin":20,"end":84},"obj":"NP"},{"id":"C3","span":{"begin":94,"end":121},"obj":"NP"},{"id":"C6","span":{"begin":183,"end":220},"obj":"NP"},{"id":"C5","span":{"begin":141,"end":220},"obj":"NP"},{"id":"C4","span":{"begin":123,"end":220},"obj":"NP"},{"id":"C7","span":{"begin":286,"end":296},"obj":"NP"},{"id":"C8","span":{"begin":524,"end":544},"obj":"NP"},{"id":"C9","span":{"begin":559,"end":581},"obj":"NP"},{"id":"C10","span":{"begin":666,"end":670},"obj":"NP"},{"id":"C11","span":{"begin":727,"end":737},"obj":"NP"},{"id":"C12","span":{"begin":790,"end":828},"obj":"NP"},{"id":"C13","span":{"begin":866,"end":876},"obj":"NP"},{"id":"C14","span":{"begin":890,"end":923},"obj":"NP"},{"id":"C15","span":{"begin":933,"end":941},"obj":"NP"},{"id":"C16","span":{"begin":942,"end":947},"obj":"NP"},{"id":"C17","span":{"begin":1187,"end":1218},"obj":"NP"},{"id":"C18","span":{"begin":1397,"end":1406},"obj":"NP"},{"id":"C20","span":{"begin":1479,"end":1500},"obj":"NP"},{"id":"C19","span":{"begin":1461,"end":1500},"obj":"NP"},{"id":"C21","span":{"begin":1529,"end":1544},"obj":"NP"},{"id":"C22","span":{"begin":1558,"end":1565},"obj":"NP"},{"id":"C24","span":{"begin":1575,"end":1578},"obj":"NP"},{"id":"C23","span":{"begin":1575,"end":1602},"obj":"NP"},{"id":"C25","span":{"begin":1604,"end":1609},"obj":"NP"},{"id":"C26","span":{"begin":1629,"end":1638},"obj":"NP"},{"id":"C27","span":{"begin":1651,"end":1660},"obj":"NP"},{"id":"C28","span":{"begin":1734,"end":1755},"obj":"NP"},{"id":"C29","span":{"begin":1769,"end":1804},"obj":"NP"},{"id":"C30","span":{"begin":1810,"end":1851},"obj":"NP"}],"relations":[{"id":"R1","pred":"coref-ident","subj":"C6","obj":"C2"},{"id":"R2","pred":"coref-ident","subj":"C5","obj":"C1"},{"id":"R3","pred":"coref-ident","subj":"C7","obj":"C5"},{"id":"R4","pred":"coref-pron","subj":"C10","obj":"C8"},{"id":"R5","pred":"coref-pron","subj":"C10","obj":"C9"},{"id":"R6","pred":"coref-ident","subj":"C11","obj":"C7"},{"id":"R7","pred":"coref-ident","subj":"C13","obj":"C11"},{"id":"R8","pred":"coref-relat","subj":"C16","obj":"C15"},{"id":"R9","pred":"coref-ident","subj":"C17","obj":"C12"},{"id":"R10","pred":"coref-ident","subj":"C18","obj":"C3"},{"id":"R11","pred":"coref-ident","subj":"C20","obj":"C5"},{"id":"R12","pred":"coref-ident","subj":"C19","obj":"C4"},{"id":"R13","pred":"coref-ident","subj":"C22","obj":"C21"},{"id":"R14","pred":"coref-pron","subj":"C24","obj":"C20"},{"id":"R15","pred":"coref-relat","subj":"C25","obj":"C23"},{"id":"R16","pred":"coref-ident","subj":"C26","obj":"C18"},{"id":"R17","pred":"coref-ident","subj":"C27","obj":"C26"},{"id":"R18","pred":"coref-ident","subj":"C28","obj":"C19"},{"id":"R19","pred":"coref-ident","subj":"C29","obj":"C17"},{"id":"R20","pred":"coref-ident","subj":"C30","obj":"C14"}],"text":"Biphasic control of nuclear factor-kappa B activation by the T cell receptor complex: role of tumor necrosis factor alpha.\nThe regulation of nuclear factor (NF)-kappa B activation by the T cell receptor (TcR)/CD3 complex in primary human T cells has been studied at various times after activation. Only p50 NF-kappa B protein bound the kappa B element of interleukin-2 receptor (IL-2R) alpha chain promoter on resting T cells. However, immediately after TcR/CD3 cross-linking (after approximately 1 h; immediate) binding of p50.p65 heterodimers was observed. p50.c-rel heterodimers were also detected bound to this sequence at early time points (7-16 h; early), and both remained active at later time points (40 h; late) after activation. This regulation takes place mainly at the level of nuclear translocation of p65 and c-rel, at immediate and early time points. Activation also induced c-rel and p105/p50 mRNA synthesis, but not p65 mRNA whose expression was constitutive. Interestingly, all those early and late events, but not the immediate ones, were inhibited by a neutralizing anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody. Similarly, cycloheximide prevented the p65 and c-rel translocation and consequent formation of active binding heterodimers, at early and late times. Cyclosporin A impaired not only early and late, but also immediate events; however, addition of TNF-alpha prevented all inhibition. These results indicate that the regulation of NF-kappa B activation during T cell activation by TcR/CD3 signals is biphasic: TcR/CD3 triggers its immediate translocation, which is transient if no TNF-alpha is present. TNF-alpha, therefore, emerges as the main factor responsible for a second phase of NF-kappa B regulation, controlling both translocation of p65 and c-rel, and new mRNA synthesis for c-rel and p105/p50."}

{"project":"pubmed-sentences-benchmark","denotations":[{"id":"S1","span":{"begin":0,"end":122},"obj":"Sentence"},{"id":"S2","span":{"begin":123,"end":297},"obj":"Sentence"},{"id":"S3","span":{"begin":298,"end":426},"obj":"Sentence"},{"id":"S4","span":{"begin":427,"end":558},"obj":"Sentence"},{"id":"S5","span":{"begin":559,"end":738},"obj":"Sentence"},{"id":"S6","span":{"begin":739,"end":865},"obj":"Sentence"},{"id":"S7","span":{"begin":866,"end":976},"obj":"Sentence"},{"id":"S8","span":{"begin":977,"end":1151},"obj":"Sentence"},{"id":"S9","span":{"begin":1152,"end":1300},"obj":"Sentence"},{"id":"S10","span":{"begin":1301,"end":1432},"obj":"Sentence"},{"id":"S11","span":{"begin":1433,"end":1650},"obj":"Sentence"},{"id":"S12","span":{"begin":1651,"end":1852},"obj":"Sentence"}],"text":"Biphasic control of nuclear factor-kappa B activation by the T cell receptor complex: role of tumor necrosis factor alpha.\nThe regulation of nuclear factor (NF)-kappa B activation by the T cell receptor (TcR)/CD3 complex in primary human T cells has been studied at various times after activation. Only p50 NF-kappa B protein bound the kappa B element of interleukin-2 receptor (IL-2R) alpha chain promoter on resting T cells. However, immediately after TcR/CD3 cross-linking (after approximately 1 h; immediate) binding of p50.p65 heterodimers was observed. p50.c-rel heterodimers were also detected bound to this sequence at early time points (7-16 h; early), and both remained active at later time points (40 h; late) after activation. This regulation takes place mainly at the level of nuclear translocation of p65 and c-rel, at immediate and early time points. Activation also induced c-rel and p105/p50 mRNA synthesis, but not p65 mRNA whose expression was constitutive. Interestingly, all those early and late events, but not the immediate ones, were inhibited by a neutralizing anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody. Similarly, cycloheximide prevented the p65 and c-rel translocation and consequent formation of active binding heterodimers, at early and late times. Cyclosporin A impaired not only early and late, but also immediate events; however, addition of TNF-alpha prevented all inhibition. These results indicate that the regulation of NF-kappa B activation during T cell activation by TcR/CD3 signals is biphasic: TcR/CD3 triggers its immediate translocation, which is transient if no TNF-alpha is present. TNF-alpha, therefore, emerges as the main factor responsible for a second phase of NF-kappa B regulation, controlling both translocation of p65 and c-rel, and new mRNA synthesis for c-rel and p105/p50."}

{"project":"GENIAcorpus","denotations":[{"id":"T1","span":{"begin":20,"end":42},"obj":"protein_molecule"},{"id":"T2","span":{"begin":61,"end":84},"obj":"protein_complex"},{"id":"T3","span":{"begin":94,"end":121},"obj":"protein_molecule"},{"id":"T4","span":{"begin":141,"end":168},"obj":"protein_molecule"},{"id":"T5","span":{"begin":187,"end":202},"obj":"protein_complex"},{"id":"T6","span":{"begin":238,"end":245},"obj":"cell_type"},{"id":"T7","span":{"begin":303,"end":325},"obj":"protein_molecule"},{"id":"T8","span":{"begin":336,"end":351},"obj":"DNA_domain_or_region"},{"id":"T9","span":{"begin":355,"end":377},"obj":"protein_molecule"},{"id":"T10","span":{"begin":379,"end":384},"obj":"protein_molecule"},{"id":"T11","span":{"begin":418,"end":425},"obj":"cell_type"},{"id":"T12","span":{"begin":454,"end":461},"obj":"protein_complex"},{"id":"T13","span":{"begin":524,"end":544},"obj":"protein_complex"},{"id":"T14","span":{"begin":559,"end":581},"obj":"protein_complex"},{"id":"T15","span":{"begin":790,"end":811},"obj":"other_name"},{"id":"T16","span":{"begin":815,"end":818},"obj":"protein_subunit"},{"id":"T17","span":{"begin":823,"end":828},"obj":"protein_subunit"},{"id":"T18","span":{"begin":933,"end":936},"obj":"protein_subunit"},{"id":"T19","span":{"begin":1086,"end":1091},"obj":"protein_molecule"},{"id":"T20","span":{"begin":1091,"end":1118},"obj":"protein_molecule"},{"id":"T21","span":{"begin":1191,"end":1194},"obj":"protein_subunit"},{"id":"T22","span":{"begin":1199,"end":1204},"obj":"protein_subunit"},{"id":"T23","span":{"begin":1205,"end":1218},"obj":"other_name"},{"id":"T24","span":{"begin":1301,"end":1314},"obj":"other_organic_compound"},{"id":"T25","span":{"begin":1397,"end":1406},"obj":"protein_molecule"},{"id":"T26","span":{"begin":1479,"end":1489},"obj":"protein_molecule"},{"id":"T27","span":{"begin":1508,"end":1525},"obj":"other_name"},{"id":"T28","span":{"begin":1529,"end":1536},"obj":"protein_complex"},{"id":"T29","span":{"begin":1558,"end":1565},"obj":"protein_complex"},{"id":"T30","span":{"begin":1629,"end":1638},"obj":"protein_molecule"},{"id":"T31","span":{"begin":1651,"end":1660},"obj":"protein_molecule"},{"id":"T32","span":{"begin":1734,"end":1744},"obj":"protein_molecule"},{"id":"T33","span":{"begin":1791,"end":1794},"obj":"protein_subunit"},{"id":"T34","span":{"begin":1799,"end":1804},"obj":"protein_subunit"},{"id":"T35","span":{"begin":1814,"end":1818},"obj":"RNA_family_or_group"},{"id":"T36","span":{"begin":1833,"end":1838},"obj":"protein_subunit"},{"id":"T37","span":{"begin":1843,"end":1851},"obj":"protein_complex"}],"text":"Biphasic control of nuclear factor-kappa B activation by the T cell receptor complex: role of tumor necrosis factor alpha.\nThe regulation of nuclear factor (NF)-kappa B activation by the T cell receptor (TcR)/CD3 complex in primary human T cells has been studied at various times after activation. Only p50 NF-kappa B protein bound the kappa B element of interleukin-2 receptor (IL-2R) alpha chain promoter on resting T cells. However, immediately after TcR/CD3 cross-linking (after approximately 1 h; immediate) binding of p50.p65 heterodimers was observed. p50.c-rel heterodimers were also detected bound to this sequence at early time points (7-16 h; early), and both remained active at later time points (40 h; late) after activation. This regulation takes place mainly at the level of nuclear translocation of p65 and c-rel, at immediate and early time points. Activation also induced c-rel and p105/p50 mRNA synthesis, but not p65 mRNA whose expression was constitutive. Interestingly, all those early and late events, but not the immediate ones, were inhibited by a neutralizing anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody. Similarly, cycloheximide prevented the p65 and c-rel translocation and consequent formation of active binding heterodimers, at early and late times. Cyclosporin A impaired not only early and late, but also immediate events; however, addition of TNF-alpha prevented all inhibition. These results indicate that the regulation of NF-kappa B activation during T cell activation by TcR/CD3 signals is biphasic: TcR/CD3 triggers its immediate translocation, which is transient if no TNF-alpha is present. TNF-alpha, therefore, emerges as the main factor responsible for a second phase of NF-kappa B regulation, controlling both translocation of p65 and c-rel, and new mRNA synthesis for c-rel and p105/p50."}